Milestone’s Etripamil Aims to Revolutionize PSVT Treatment
Company Announcements

Milestone’s Etripamil Aims to Revolutionize PSVT Treatment

Milestone Pharmaceuticals (MIST) has released an update.

Milestone Pharmaceuticals has announced the resubmission of its New Drug Application to the FDA for etripamil, a promising treatment for the heart condition paroxysmal supraventricular tachycardia (PSVT). The company addressed all concerns from the FDA’s initial refusal to file, enhancing the chances for approval of this potentially vital nasal spray for PSVT patients. This treatment could change the game for two million Americans suffering from the distressing and unpredictable episodes of rapid heartbeats associated with PSVT.

For further insights into MIST stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMilestone partner announces Phase 3 study of etripamil met primary endpoint
TipRanks Auto-Generated NewsdeskMilestone Pharmaceuticals Welcomes New Directors and Auditor
TheFlyMilestone Pharmaceuticals appoints Joseph Papa to board of directors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App